The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
10 x '20 Progress--Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America
Open accessAbstract
Infections caused by antibiotic-resistant bacteria, especially the "ESKAPE" pathogens, continue to increase in frequency and cause significant morbidity and mortality. New antimicrobial agents are greatly needed to treat infections caused by gram-negative bacilli (GNB) resistant to currently available agents. The Infectious Diseases Society of America (IDSA) continues to propose legislative, regulatory, and funding solutions to this continuing crisis. The current report updates the status of development and approval of systemic antibiotics in the United States as of early 2013. Only 2 new antibiotics have been approved since IDSA's 2009 pipeline status report, and the number of new antibiotics annually approved for marketing in the United States continues to decline. We identified 7 drugs in clinical development for treatment of infections caused by resistant GNB. None of these agents was included in our 2009 list of antibacterial compounds in phase 2 or later development, but unfortunately none addresses the entire spectrum of clinically relevant GNB resistance. Our survey demonstrates some progress in development of new antibacterial drugs that target infections caused by resistant GNB, but progress remains alarmingly elusive. IDSA stresses our conviction that the antibiotic pipeline problem can be solved by the collaboration of global leaders to develop creative incentives that will stimulate new antibacterial research and development. Our aim is the creation of a sustainable global antibacterial drug research and development enterprise with the power in the short term to develop 10 new, safe, and efficacious systemically administered antibiotics by 2020 as called for in IDSA's "10 × '20 Initiative."
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958
Self-citationDellit, T. H., Owens, R. C., McGowan, J. E., Gerding, D. N., Weinstein, R. A., Burke, J. P., Huskins, W. C., Paterson, D. L., Fishman, N. O., Carpenter, C. F., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/510393 · Cited by 3,362
Infectious Diseases Society of America
Enders, J. F. (1969) · Journal of Infectious Diseases · doi:10.1093/infdis/119.3.317 · Cited by 3,286
A functional classification scheme for beta-lactamases and its correlation with molecular structure
Bush, K., Jacoby, G. A., & Medeiros, A. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.6.1211 · Cited by 2,475
Updated Functional Classification of β-Lactamases
Bush, K., & Jacoby, G. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01009-09 · Cited by 2,367
Federal Funding for the Study of Antimicrobial Resistance in Nosocomial Pathogens: No ESKAPE
Rice, L. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/533452 · Cited by 2,310
Spellberg, B., Guidos, R., Gilbert, D., Bradley, J., Boucher, H. W., Scheld, W. M., Bartlett, J. G., Edwards, J., & the Infectious Diseases Society of America (2008) · Clinical Infectious Diseases · doi:10.1086/524891 · Cited by 1,642
Self-citationAntibiotic-Resistant Bugs in the 21st Century — A Clinical Super-Challenge
Arias, C. A., & Murray, B. E. (2009) · New England Journal of Medicine · doi:10.1056/nejmp0804651 · Cited by 1,027
Self-citationTrends in antimicrobial drug development: Implications for the future
Spellberg, B., Powers, J. H., Brass, E. P., Miller, L. G., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/420937 · Cited by 867
Combating Antimicrobial Resistance: Policy Recommendations to Save Lives
Infectious Diseases Society of America (IDSA) (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir153 · Cited by 733
The evolving threat of antimicrobial resistance: Options for action
Kapi, A. (2014) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 714
Fishman, N., Society for Healthcare Epidemiology of America, Infectious Diseases Society of America, & Pediatric Infectious Diseases Society (2012) · Infection Control & Hospital Epidemiology · doi:10.1086/665010 · Cited by 677
Vital signs: carbapenem-resistant Enterobacteriaceae.
(2013) · PubMed Central · Cited by 604
The Perpetual Challenge of Infectious Diseases
Fauci, A. S., & Morens, D. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1108296 · Cited by 517
The 10 × ‘20 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020
(2010) · Clinical Infectious Diseases · doi:10.1086/652237 · Cited by 484
Antibiotics in the clinical pipeline in 2011
Butler, M. S., & Cooper, M. A. (2011) · The Journal of Antibiotics · doi:10.1038/ja.2011.44 · Cited by 272
Livermore, D. M., Mushtaq, S., Warner, M., Zhang, J., Maharjan, S., Doumith, M., & Woodford, N. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00756-10 · Cited by 261
Page, M. G. P., Dantier, C., & Desarbre, E. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01525-09 · Cited by 227
ESBLs: A Clear and Present Danger?
Dhillon, R. H.-P., & Clark, J. (2012) · Critical Care Research and Practice · doi:10.1155/2012/625170 · Cited by 192
Llarrull, L. I., Testero, S. A., Fisher, J. F., & Mobashery, S. (2010) · Current Opinion in Microbiology · doi:10.1016/j.mib.2010.09.008 · Cited by 170
Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic
Grossman, T. H., Starosta, A. L., Fyfe, C., O'Brien, W., Rothstein, D. M., Mikolajka, A., Wilson, D. N., & Sutcliffe, J. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06187-11 · Cited by 162
Kallen, A. J., Hidrón, A., Patel, J. B., & Srinivasan, A. (2010) · Infection Control and Hospital Epidemiology · doi:10.1086/652152 · Cited by 158
Hirsch, E. B., Ledesma, K. R., Chang, K., Schwartz, M. S., Motyl, M. R., & Tam, V. H. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05927-11 · Cited by 145
Trends in antimicrobial drug development: Implications for the future
Sergio Mella, M. (2005) · Revista chilena de infectología · doi:10.4067/s0716-10182005000200011 · Cited by 144
In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters
Mushtaq, S., Warner, M., & Livermore, D. M. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq306 · Cited by 129
New β-lactam antibiotics and β-lactamase inhibitors
Bush, K., & Macielag, M. J. (2010) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2010.515588 · Cited by 120
Combating evolution with intelligent design: the neoglycoside ACHN-490
Armstrong, E. S., & Miller, G. H. (2010) · Current Opinion in Microbiology · doi:10.1016/j.mib.2010.09.004 · Cited by 107
Infectious Diseases Society of America (IDSA) (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis688 · Cited by 103
Levasseur, P., Girard, A.-M., Claudon, M., Goossens, H., Black, M. T., Coleman, K., & Miossec, C. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06064-11 · Cited by 102
Talbot, G. H., Powers, J. H., Fleming, T. R., Siuciak, J. A., Bradley, J. S., Boucher, H. W., & on behalf of the CABP-ABSSSI Project Team (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis566 · Cited by 84
Self-citationLagacé-Wiens, P. R. S., Tailor, F., Simner, P. J., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01722-10 · Cited by 80
Endimiani, A., Hujer, K. M., Hujer, A. M., Pulse, M., Weiss, W. J., & Bonomo, R. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01198-10 · Cited by 77
Self-citationCastanheira, M., Sader, H. S., Farrell, D. J., Mendes, R. E., & Jones, R. N. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00817-12 · Cited by 74
Self-citationPérez, F., & Bonomo, R. A. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir793 · Cited by 70
Self-citationWalkty, A. J., DeCorby, M. R., Lagacé-Wiens, P. R. S., Karlowsky, J. A., Hoban, D. J., & Zhanel, G. G. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01696-10 · Cited by 65
Russo, T. A., Page, M. G. P., Beanan, J. M., Olson, R., Hujer, A. M., Hujer, K. M., Jacobs, M. R., Bajaksouzian, S., Endimiani, A., & Bonomo, R. A. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr013 · Cited by 63
Self-citationSpellberg, B. J., & Talbot, G. H. (2010) · Clinical Infectious Diseases · doi:10.1086/653065 · Cited by 57
Self-citationNew antimicrobial agents on the horizon
Bush, K., & Pucci, M. J. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.07.077 · Cited by 53
New molecules from old classes: revisiting the development of beta-lactams.
Page, M. G. P., & Heim, J. (2009) · PubMed · Cited by 25
β‐Lactam antimicrobials: what have you done for me lately?
Talbot, G. H. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06809.x · Cited by 15
Self-citation
Cited by
The re-emergence of natural products for drug discovery in the genomics era
Harvey, A. L., Edrada-Ebel, R., & Quinn, R. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4510 · Cited by 2,572
Llor, C., & Bjerrum, L. (2014) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098614554919 · Cited by 2,079
Antibiotics and Bacterial Resistance in the 21st Century
Fair, R. J., & Tor, Y. (2014) · Perspectives in Medicinal Chemistry · doi:10.4137/pmc.s14459 · Cited by 1,955
The Challenge of Efflux-Mediated Antibiotic Resistance in Gram-Negative Bacteria
Li, X.-Z., Plésiat, P., & Nikaido, H. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00117-14 · Cited by 1,614
The global threat of antimicrobial resistance: science for intervention.
Roca, I., Akova, M., Baquero, F., Carlet, J., Cavaleri, M., Coenen, S., Cohen, J., Findlay, D., Gyssens, I., Heure, O. E., et al. (2015) · New Microbes and New Infections · doi:10.1016/j.nmni.2015.02.007 · Cited by 1,106
Metadata
- Authors
- Boucher, H. W., Talbot, G. H., Benjamin, D. K., Bradley, J., Guidos, R. J., Jones, R. N., Murray, B. E., Bonomo, R. A., Gilbert, D., & for the Infectious Diseases Society of America
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-04-17
- Volume
- 56
- Issue
- 12
- Pages
- 1685-1694
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2129842338
- Cited by
- 700
- References
- 41
- FWCI
- 44.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.